Together with Hospital Clínic de Barcelona, Enzyme works with Artificial Intelligence algorithms applied to the diagnosis of Idiopathic Pulmonary Fibrosis.
Enzyme has received the E-nnova Health 2022 award for the initiative "Development of Artificial Intelligence algorithms to support the diagnosis of Idiopathic Pulmonary Fibrosis (IPF)" in the category of "Big Data and Artificial Intelligence".
The initiative is a joint effort of Enzyme and Hospital Clínic de Barcelona. It is being developed within the framework of Komombo, the platform that offers support for pathological diagnosis, through collaborative software powered by Enzyme's Artificial Intelligence. Both organizations share the vision of driving the research, development and adoption of tools based on Artificial Intelligence, Blockchain and Data Science, thus facilitating the detection and diagnosis of diseases.
The awards ceremony organized by Diario Médico and Correo Farmacéutico, Unidad Editorial's leading specialized media in the healthcare sector, took place at the Espacio Pablo VI in Madrid on Tuesday, October 25, 2022. The event was attended by a large number of sector representatives, as well as all the award-winning companies, who received their awards from Miguel G. Corral, their director of the Medicine and Health area.
The E-nnova Health awards recognize the work carried out in 2022 by professionals, institutions and companies whose digital initiatives provide differential value, contributing to the sustainability of the system and improving patients' lives.
Álvaro Ortín, CEO of Enzyme, points out that "the Enzyme Group has been working for years to promote the culture of digital transformation in companies through Artificial Intelligence. This E-nnova Health 2022 recognition is the result of all the work done in the healthcare field, which is bearing its first results to improve the quality of life of patients, the work of medical professionals and the transformation of the healthcare sector".
Receiving the award: Yan Bello (Chief Product & Innovation Officer - CPIO, Enzyme), Daniel Martínez (Pathologist, Hospital Clínic de Barcelona), Pedro Arellano (General Director of Enzyme) and Luis M. Artiles (Director of Innovation, Enzyme).
E-nnova Health 2022 Award Ceremony